Microbiotica reported Phase Ib results for MB‑310, an orally delivered live biotherapeutic for ulcerative colitis, showing 12 of 19 treated patients reached clinical remission versus 3 of 10 on placebo. Responders maintained remission during a three‑month follow‑up and achieved complete resolution of rectal bleeding in many cases. Researchers also noted histological improvements and markers of mucosal healing in responders, bolstering the biological plausibility of the therapeutic effect. The study was short and limited in size but provides a proof‑of‑concept signal for MB‑310 in inflammatory bowel disease. Microbiotica said it will weigh next steps for a larger, controlled program; the result adds momentum to the live‑biotherapeutic category despite recent sector-wide headwinds.